性器ヘルペス治療薬の世界市場機会分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 14
1.2 List of Figures 17
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 19
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 23
3.2 Quality of Life 26
3.3 Symptoms 27
3.4 Disease Management 28
3.4.1 Diagnosis 28
3.4.2 Antiviral Therapy 31
3.4.3 Management of GH in Specific Patient Populations 34
3.4.4 Supportive Measures 37
4 Epidemiology 39
4.1 Disease Background 39
4.2 Risk Factors and Comorbidities 40
4.3 Global Trends 42
4.4 Forecast Methodology 43
4.4.1 Sources Used 44
4.4.2 Sources Not Used 50
4.4.3 Forecast Assumptions and Methods 51
4.5 Epidemiological Forecast of GH (2013-2023) 61
4.5.1 Diagnosed Incident Cases of GH 61
4.5.2 Diagnosed Incident Cases of GH Segmented by Strain 63
4.5.3 Diagnosed Incident Cases of GH Segmented by Sex 65
4.5.4 Number of Persons Diagnosed with Herpes Simplex Virus-1 GH Experiencing Recurrences During the First Year of Diagnosis 67
4.5.5 Number of Persons Diagnosed with Herpes Simplex Virus-2 GH Experiencing Recurrences During the First Year of Diagnosis 68
4.5.6 Diagnosed Prevalent Cases of Herpes Simplex Virus-1 Only GH 69
4.5.7 Diagnosed Prevalent Cases of Herpes Simplex Virus-2 Only GH 71
4.5.8 Diagnosed Prevalent Cases of Herpes Simplex Virus-1 and Herpes Simplex Virus-2 Co-infection GH 72
4.6 Discussion 74
4.6.1 Epidemiological Forecast Insight 74
4.6.2 Limitations of the Analysis 74
4.6.3 Strengths of the Analysis 75
5 Current Treatment Options 77
5.1 Overview 77
5.2 Product Profiles – Antivirals 80
5.2.1 Acyclovir 80
5.2.2 Valacyclovir 85
5.2.3 Famciclovir 90
5.2.4 Other Marketed Products 96
6 Unmet Needs Assessment and Opportunity Analysis 101
6.1 Overview 101
6.2 Unmet Needs Analysis 105
6.2.1 Unmet Need: Novel Treatment Options That Reduce GH Transmission and Recurrence 105
6.2.2 Unmet Need: Therapies with More Convenient Dosing Schedules 108
6.2.3 Unmet Need: Safe and Efficacious Therapeutic Interventions for Difficult-to-Treat Patient Populations 110
6.2.4 Unmet Need: Increased Public Awareness and Acceptance of GH 111
6.2.5 Unmet Need: Improved Physician Education on the Importance of Proactively Diagnosing and Treating GH 113
6.3 Opportunity Analysis 114
6.3.1 Opportunity: Develop Therapeutic GH Vaccines 114
6.3.2 Opportunity: Develop Prophylactic GH Vaccines 117
6.3.3 Opportunity: Develop Novel Antiviral Treatments that Possess Novel Mechanisms of Action 120
6.3.4 Opportunity: Leverage Novel Diagnostic Tools alongside Public Awareness Initiatives to Improve GH Diagnosis Rates 122
7 Research and Development Strategies 124
7.1 Overview 124
7.2 Technological Approaches to Vaccine Development 125
7.2.1 Vaccine Antigen Selection 125
7.2.2 Selection of Adjuvants and Co-stimulants 128
7.2.3 Prioritizing Therapeutic Vaccines that Target Herpes Simplex Virus-2 130
7.3 Development of Antivirals that Possess Novel Mechanisms of Action 131
7.4 Collaboration, Licensing, and Partnerships 133
7.5 Clinical Trial Design 134
7.5.1 Current Clinical Trial Design 134
7.5.2 Selection and Enrollment of Clinical Trial Participants 138
7.5.3 Efficacy Endpoint Selection 140
7.5.4 Genital Swabbing Test 143
8 Pipeline Assessment 145
8.1 Overview 145
8.2 Promising Products in Clinical Development 146
8.2.1 Amenamevir 146
8.2.2 HerpV 153
8.2.3 GEN-003 157
8.3 Promising Products in Early-Stage Clinical Development 164
8.3.1 VCL-HB01 and VCL-HM01 165
8.3.2 HSV529 166
8.3.3 HSV-2 DNA Vaccine 168
8.3.4 Brincidofovir 169
8.3.5 G103 169
8.3.6 Pritelivir 169
8.4 Other Innovative Approaches 170
8.4.1 Vaccines in Preclinical Development 171
8.4.2 Other Products in Preclinical Development 172
9 Pipeline Valuation Analysis 173
9.1 Clinical Benchmark of Key Pipeline Drugs 173
9.2 Commercial Benchmark of Key Pipeline Drugs 176
9.3 Competitive Assessment 178
9.4 Top Line Five Year Forecast 181
9.4.1 US 185
9.4.2 5EU 185
9.4.3 Japan 186
10 Appendix 187
10.1 Bibliography 187
10.2 Abbreviations 206
10.3 Methodology 210
10.4 Forecasting Methodology 210
10.4.1 Diagnosed GH Patients 210
10.4.2 Drug-Treated GH Patients 211
10.4.3 Drugs Included in Each Therapeutic Class 211
10.4.4 Launch and Patent Expiry Dates 211
10.4.5 General Pricing Assumptions 212
10.4.6 Individual Drug Assumptions 213
10.4.7 Pricing of Pipeline Agents 217
10.5 Primary Research — Key Opinion Leaders Interviewed for this Report 218
10.6 Primary Research — Prescriber Survey 219
10.7 About the Authors 220
10.7.1 Author 220
10.7.2 Epidemiologist 220
10.7.3 Therapy Area Director 221
10.7.4 Global Head of Healthcare 221
10.8 About GlobalData 222
10.9 Disclaimer 222